chronic obstructive pulmonary disease dupixent news

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United States.

Hosted on MSN · 14h

FDA Approves Dupixent Injections For People Struggling With COPD Symptoms

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with elevated eosinophil levels. Clinical trials show that Dupixent reduces COPD exacerbations and improves symptoms when combined with inhaled medications,

Monthly Prescribing Reference · 17h

Dupixent Approved as Add-On Maintenance Therapy in COPD

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Sanofi blockbuster drug wins clearance in US for lung disease

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Nasdaq3d

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyps ...

Yahoo Finance3d

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results